nodes	percent_of_prediction	percent_of_DWPC	metapath
Milnacipran—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.0043	0.0043	CcSEcCtD
Milnacipran—Neutropenia—Carmustine—lymphatic system cancer	0.00428	0.00428	CcSEcCtD
Milnacipran—Hypoaesthesia—Bleomycin—lymphatic system cancer	0.00418	0.00418	CcSEcCtD
Milnacipran—Dyspnoea—Teniposide—lymphatic system cancer	0.00413	0.00413	CcSEcCtD
Milnacipran—Dysuria—Vincristine—lymphatic system cancer	0.00409	0.00409	CcSEcCtD
Milnacipran—Neutropenia—Vincristine—lymphatic system cancer	0.00409	0.00409	CcSEcCtD
Milnacipran—Infection—Fludarabine—lymphatic system cancer	0.00404	0.00404	CcSEcCtD
Milnacipran—Erectile dysfunction—Vincristine—lymphatic system cancer	0.00403	0.00403	CcSEcCtD
Milnacipran—Decreased appetite—Teniposide—lymphatic system cancer	0.00402	0.00402	CcSEcCtD
Milnacipran—Vomiting—Mechlorethamine—lymphatic system cancer	0.00399	0.00399	CcSEcCtD
Milnacipran—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00399	0.00399	CcSEcCtD
Milnacipran—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.00398	0.00398	CcSEcCtD
Milnacipran—Neutropenia—Mitoxantrone—lymphatic system cancer	0.00398	0.00398	CcSEcCtD
Milnacipran—Urinary tract infection—Carmustine—lymphatic system cancer	0.00397	0.00397	CcSEcCtD
Milnacipran—Rash—Mechlorethamine—lymphatic system cancer	0.00396	0.00396	CcSEcCtD
Milnacipran—Upper respiratory tract infection—Mitoxantrone—lymphatic system cancer	0.00396	0.00396	CcSEcCtD
Milnacipran—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00395	0.00395	CcSEcCtD
Milnacipran—Weight decreased—Vincristine—lymphatic system cancer	0.00395	0.00395	CcSEcCtD
Milnacipran—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00393	0.00393	CcSEcCtD
Milnacipran—Erectile dysfunction—Mitoxantrone—lymphatic system cancer	0.00392	0.00392	CcSEcCtD
Milnacipran—Flushing—Bleomycin—lymphatic system cancer	0.0039	0.0039	CcSEcCtD
Milnacipran—Anorexia—Fludarabine—lymphatic system cancer	0.00388	0.00388	CcSEcCtD
Milnacipran—Weight decreased—Mitoxantrone—lymphatic system cancer	0.00385	0.00385	CcSEcCtD
Milnacipran—Proteinuria—Methotrexate—lymphatic system cancer	0.00385	0.00385	CcSEcCtD
Milnacipran—Protein urine present—Methotrexate—lymphatic system cancer	0.00379	0.00379	CcSEcCtD
Milnacipran—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00378	0.00378	CcSEcCtD
Milnacipran—Chills—Bleomycin—lymphatic system cancer	0.00377	0.00377	CcSEcCtD
Milnacipran—Nausea—Mechlorethamine—lymphatic system cancer	0.00373	0.00373	CcSEcCtD
Milnacipran—Urinary tract infection—Mitoxantrone—lymphatic system cancer	0.00369	0.00369	CcSEcCtD
Milnacipran—Urticaria—Teniposide—lymphatic system cancer	0.00368	0.00368	CcSEcCtD
Milnacipran—Abdominal pain—Teniposide—lymphatic system cancer	0.00366	0.00366	CcSEcCtD
Milnacipran—Body temperature increased—Teniposide—lymphatic system cancer	0.00366	0.00366	CcSEcCtD
Milnacipran—Paraesthesia—Fludarabine—lymphatic system cancer	0.00365	0.00365	CcSEcCtD
Milnacipran—Hallucination—Carmustine—lymphatic system cancer	0.00365	0.00365	CcSEcCtD
Milnacipran—Hypoaesthesia—Carmustine—lymphatic system cancer	0.00365	0.00365	CcSEcCtD
Milnacipran—Dyspnoea—Fludarabine—lymphatic system cancer	0.00363	0.00363	CcSEcCtD
Milnacipran—Haematuria—Mitoxantrone—lymphatic system cancer	0.00362	0.00362	CcSEcCtD
Milnacipran—Oedema peripheral—Carmustine—lymphatic system cancer	0.00361	0.00361	CcSEcCtD
Milnacipran—Connective tissue disorder—Carmustine—lymphatic system cancer	0.0036	0.0036	CcSEcCtD
Milnacipran—Dyspepsia—Fludarabine—lymphatic system cancer	0.00358	0.00358	CcSEcCtD
Milnacipran—Decreased appetite—Fludarabine—lymphatic system cancer	0.00354	0.00354	CcSEcCtD
Milnacipran—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00351	0.00351	CcSEcCtD
Milnacipran—Fatigue—Fludarabine—lymphatic system cancer	0.00351	0.00351	CcSEcCtD
Milnacipran—Hallucination—Vincristine—lymphatic system cancer	0.00348	0.00348	CcSEcCtD
Milnacipran—Hypoaesthesia—Vincristine—lymphatic system cancer	0.00348	0.00348	CcSEcCtD
Milnacipran—Constipation—Fludarabine—lymphatic system cancer	0.00348	0.00348	CcSEcCtD
Milnacipran—Urinary tract disorder—Vincristine—lymphatic system cancer	0.00345	0.00345	CcSEcCtD
Milnacipran—Connective tissue disorder—Vincristine—lymphatic system cancer	0.00344	0.00344	CcSEcCtD
Milnacipran—Urethral disorder—Vincristine—lymphatic system cancer	0.00343	0.00343	CcSEcCtD
Milnacipran—Eye disorder—Carmustine—lymphatic system cancer	0.00342	0.00342	CcSEcCtD
Milnacipran—Hypersensitivity—Teniposide—lymphatic system cancer	0.00341	0.00341	CcSEcCtD
Milnacipran—Hepatitis—Mitoxantrone—lymphatic system cancer	0.00341	0.00341	CcSEcCtD
Milnacipran—Flushing—Carmustine—lymphatic system cancer	0.0034	0.0034	CcSEcCtD
Milnacipran—Asthenia—Teniposide—lymphatic system cancer	0.00332	0.00332	CcSEcCtD
Milnacipran—Cystitis noninfective—Methotrexate—lymphatic system cancer	0.0033	0.0033	CcSEcCtD
Milnacipran—Pruritus—Teniposide—lymphatic system cancer	0.00327	0.00327	CcSEcCtD
Milnacipran—Leukopenia—Bleomycin—lymphatic system cancer	0.00327	0.00327	CcSEcCtD
Milnacipran—Cystitis—Methotrexate—lymphatic system cancer	0.00326	0.00326	CcSEcCtD
Milnacipran—Cardiac disorder—Vincristine—lymphatic system cancer	0.00325	0.00325	CcSEcCtD
Milnacipran—Body temperature increased—Fludarabine—lymphatic system cancer	0.00322	0.00322	CcSEcCtD
Milnacipran—Mental disorder—Carmustine—lymphatic system cancer	0.00321	0.00321	CcSEcCtD
Milnacipran—Malnutrition—Carmustine—lymphatic system cancer	0.00319	0.00319	CcSEcCtD
Milnacipran—Angiopathy—Vincristine—lymphatic system cancer	0.00317	0.00317	CcSEcCtD
Milnacipran—Diarrhoea—Teniposide—lymphatic system cancer	0.00317	0.00317	CcSEcCtD
Milnacipran—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00315	0.00315	CcSEcCtD
Milnacipran—Chest pain—Bleomycin—lymphatic system cancer	0.00311	0.00311	CcSEcCtD
Milnacipran—Mental disorder—Vincristine—lymphatic system cancer	0.00306	0.00306	CcSEcCtD
Milnacipran—Chills—Mitoxantrone—lymphatic system cancer	0.00306	0.00306	CcSEcCtD
Milnacipran—Bladder pain—Methotrexate—lymphatic system cancer	0.00306	0.00306	CcSEcCtD
Milnacipran—Vision blurred—Carmustine—lymphatic system cancer	0.00301	0.00301	CcSEcCtD
Milnacipran—Hypersensitivity—Fludarabine—lymphatic system cancer	0.003	0.003	CcSEcCtD
Milnacipran—Tremor—Carmustine—lymphatic system cancer	0.00299	0.00299	CcSEcCtD
Milnacipran—Infection—Bleomycin—lymphatic system cancer	0.00296	0.00296	CcSEcCtD
Milnacipran—Vomiting—Teniposide—lymphatic system cancer	0.00294	0.00294	CcSEcCtD
Milnacipran—Agitation—Carmustine—lymphatic system cancer	0.00293	0.00293	CcSEcCtD
Milnacipran—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00292	0.00292	CcSEcCtD
Milnacipran—Asthenia—Fludarabine—lymphatic system cancer	0.00292	0.00292	CcSEcCtD
Milnacipran—Rash—Teniposide—lymphatic system cancer	0.00292	0.00292	CcSEcCtD
Milnacipran—Dermatitis—Teniposide—lymphatic system cancer	0.00292	0.00292	CcSEcCtD
Milnacipran—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.0029	0.0029	CcSEcCtD
Milnacipran—Headache—Teniposide—lymphatic system cancer	0.0029	0.0029	CcSEcCtD
Milnacipran—Pruritus—Fludarabine—lymphatic system cancer	0.00288	0.00288	CcSEcCtD
Milnacipran—Leukopenia—Carmustine—lymphatic system cancer	0.00286	0.00286	CcSEcCtD
Milnacipran—Anorexia—Bleomycin—lymphatic system cancer	0.00284	0.00284	CcSEcCtD
Milnacipran—Agitation—Vincristine—lymphatic system cancer	0.0028	0.0028	CcSEcCtD
Milnacipran—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00279	0.00279	CcSEcCtD
Milnacipran—Hypotension—Bleomycin—lymphatic system cancer	0.00279	0.00279	CcSEcCtD
Milnacipran—Diarrhoea—Fludarabine—lymphatic system cancer	0.00278	0.00278	CcSEcCtD
Milnacipran—Convulsion—Carmustine—lymphatic system cancer	0.00276	0.00276	CcSEcCtD
Milnacipran—Hypertension—Carmustine—lymphatic system cancer	0.00275	0.00275	CcSEcCtD
Milnacipran—Nausea—Teniposide—lymphatic system cancer	0.00275	0.00275	CcSEcCtD
Milnacipran—Leukopenia—Vincristine—lymphatic system cancer	0.00273	0.00273	CcSEcCtD
Milnacipran—Chest pain—Carmustine—lymphatic system cancer	0.00272	0.00272	CcSEcCtD
Milnacipran—Anxiety—Carmustine—lymphatic system cancer	0.00271	0.00271	CcSEcCtD
Milnacipran—Paraesthesia—Bleomycin—lymphatic system cancer	0.00268	0.00268	CcSEcCtD
Milnacipran—Dyspnoea—Bleomycin—lymphatic system cancer	0.00266	0.00266	CcSEcCtD
Milnacipran—Renal failure acute—Methotrexate—lymphatic system cancer	0.00266	0.00266	CcSEcCtD
Milnacipran—Leukopenia—Mitoxantrone—lymphatic system cancer	0.00265	0.00265	CcSEcCtD
Milnacipran—Convulsion—Vincristine—lymphatic system cancer	0.00264	0.00264	CcSEcCtD
Milnacipran—Hypertension—Vincristine—lymphatic system cancer	0.00263	0.00263	CcSEcCtD
Milnacipran—Decreased appetite—Bleomycin—lymphatic system cancer	0.00259	0.00259	CcSEcCtD
Milnacipran—Infection—Carmustine—lymphatic system cancer	0.00259	0.00259	CcSEcCtD
Milnacipran—Vomiting—Fludarabine—lymphatic system cancer	0.00259	0.00259	CcSEcCtD
Milnacipran—Convulsion—Mitoxantrone—lymphatic system cancer	0.00257	0.00257	CcSEcCtD
Milnacipran—Rash—Fludarabine—lymphatic system cancer	0.00256	0.00256	CcSEcCtD
Milnacipran—Dermatitis—Fludarabine—lymphatic system cancer	0.00256	0.00256	CcSEcCtD
Milnacipran—Hypertension—Mitoxantrone—lymphatic system cancer	0.00256	0.00256	CcSEcCtD
Milnacipran—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00255	0.00255	CcSEcCtD
Milnacipran—Headache—Fludarabine—lymphatic system cancer	0.00255	0.00255	CcSEcCtD
Milnacipran—Tachycardia—Carmustine—lymphatic system cancer	0.00254	0.00254	CcSEcCtD
Milnacipran—Chest pain—Mitoxantrone—lymphatic system cancer	0.00252	0.00252	CcSEcCtD
Milnacipran—Anxiety—Mitoxantrone—lymphatic system cancer	0.00252	0.00252	CcSEcCtD
Milnacipran—Anorexia—Carmustine—lymphatic system cancer	0.00248	0.00248	CcSEcCtD
Milnacipran—Infection—Vincristine—lymphatic system cancer	0.00247	0.00247	CcSEcCtD
Milnacipran—Nervous system disorder—Vincristine—lymphatic system cancer	0.00244	0.00244	CcSEcCtD
Milnacipran—Thrombocytopenia—Vincristine—lymphatic system cancer	0.00243	0.00243	CcSEcCtD
Milnacipran—Hypotension—Carmustine—lymphatic system cancer	0.00243	0.00243	CcSEcCtD
Milnacipran—Nausea—Fludarabine—lymphatic system cancer	0.00242	0.00242	CcSEcCtD
Milnacipran—Infection—Mitoxantrone—lymphatic system cancer	0.0024	0.0024	CcSEcCtD
Milnacipran—Hyperhidrosis—Vincristine—lymphatic system cancer	0.0024	0.0024	CcSEcCtD
Milnacipran—Shock—Mitoxantrone—lymphatic system cancer	0.00238	0.00238	CcSEcCtD
Milnacipran—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00237	0.00237	CcSEcCtD
Milnacipran—Urticaria—Bleomycin—lymphatic system cancer	0.00237	0.00237	CcSEcCtD
Milnacipran—Anorexia—Vincristine—lymphatic system cancer	0.00237	0.00237	CcSEcCtD
Milnacipran—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00236	0.00236	CcSEcCtD
Milnacipran—Body temperature increased—Bleomycin—lymphatic system cancer	0.00236	0.00236	CcSEcCtD
Milnacipran—Insomnia—Carmustine—lymphatic system cancer	0.00235	0.00235	CcSEcCtD
Milnacipran—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00235	0.00235	CcSEcCtD
Milnacipran—Irritability—Methotrexate—lymphatic system cancer	0.00234	0.00234	CcSEcCtD
Milnacipran—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00234	0.00234	CcSEcCtD
Milnacipran—Paraesthesia—Carmustine—lymphatic system cancer	0.00234	0.00234	CcSEcCtD
Milnacipran—Hypotension—Vincristine—lymphatic system cancer	0.00232	0.00232	CcSEcCtD
Milnacipran—Dyspnoea—Carmustine—lymphatic system cancer	0.00232	0.00232	CcSEcCtD
Milnacipran—Somnolence—Carmustine—lymphatic system cancer	0.00231	0.00231	CcSEcCtD
Milnacipran—Anorexia—Mitoxantrone—lymphatic system cancer	0.00231	0.00231	CcSEcCtD
Milnacipran—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.00227	0.00227	CcSEcCtD
Milnacipran—Decreased appetite—Carmustine—lymphatic system cancer	0.00226	0.00226	CcSEcCtD
Milnacipran—Hypotension—Mitoxantrone—lymphatic system cancer	0.00226	0.00226	CcSEcCtD
Milnacipran—Insomnia—Vincristine—lymphatic system cancer	0.00225	0.00225	CcSEcCtD
Milnacipran—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00225	0.00225	CcSEcCtD
Milnacipran—Paraesthesia—Vincristine—lymphatic system cancer	0.00223	0.00223	CcSEcCtD
Milnacipran—Constipation—Carmustine—lymphatic system cancer	0.00223	0.00223	CcSEcCtD
Milnacipran—Breast disorder—Methotrexate—lymphatic system cancer	0.00222	0.00222	CcSEcCtD
Milnacipran—Hypersensitivity—Bleomycin—lymphatic system cancer	0.0022	0.0022	CcSEcCtD
Milnacipran—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00217	0.00217	CcSEcCtD
Milnacipran—Decreased appetite—Vincristine—lymphatic system cancer	0.00216	0.00216	CcSEcCtD
Milnacipran—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00216	0.00216	CcSEcCtD
Milnacipran—Somnolence—Mitoxantrone—lymphatic system cancer	0.00215	0.00215	CcSEcCtD
Milnacipran—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00215	0.00215	CcSEcCtD
Milnacipran—Fatigue—Vincristine—lymphatic system cancer	0.00214	0.00214	CcSEcCtD
Milnacipran—Asthenia—Bleomycin—lymphatic system cancer	0.00214	0.00214	CcSEcCtD
Milnacipran—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00213	0.00213	CcSEcCtD
Milnacipran—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00213	0.00213	CcSEcCtD
Milnacipran—Constipation—Vincristine—lymphatic system cancer	0.00213	0.00213	CcSEcCtD
Milnacipran—Pruritus—Bleomycin—lymphatic system cancer	0.00211	0.00211	CcSEcCtD
Milnacipran—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.0021	0.0021	CcSEcCtD
Milnacipran—Fatigue—Mitoxantrone—lymphatic system cancer	0.00209	0.00209	CcSEcCtD
Milnacipran—Constipation—Mitoxantrone—lymphatic system cancer	0.00207	0.00207	CcSEcCtD
Milnacipran—Abdominal pain—Carmustine—lymphatic system cancer	0.00206	0.00206	CcSEcCtD
Milnacipran—Body temperature increased—Carmustine—lymphatic system cancer	0.00206	0.00206	CcSEcCtD
Milnacipran—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00203	0.00203	CcSEcCtD
Milnacipran—Dysuria—Methotrexate—lymphatic system cancer	0.00198	0.00198	CcSEcCtD
Milnacipran—Neutropenia—Methotrexate—lymphatic system cancer	0.00198	0.00198	CcSEcCtD
Milnacipran—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00198	0.00198	CcSEcCtD
Milnacipran—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.00197	0.00197	CcSEcCtD
Milnacipran—Abdominal pain—Vincristine—lymphatic system cancer	0.00196	0.00196	CcSEcCtD
Milnacipran—Body temperature increased—Vincristine—lymphatic system cancer	0.00196	0.00196	CcSEcCtD
Milnacipran—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Milnacipran—Urticaria—Mitoxantrone—lymphatic system cancer	0.00192	0.00192	CcSEcCtD
Milnacipran—Hypersensitivity—Carmustine—lymphatic system cancer	0.00192	0.00192	CcSEcCtD
Milnacipran—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00191	0.00191	CcSEcCtD
Milnacipran—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00191	0.00191	CcSEcCtD
Milnacipran—Vomiting—Bleomycin—lymphatic system cancer	0.0019	0.0019	CcSEcCtD
Milnacipran—Rash—Bleomycin—lymphatic system cancer	0.00188	0.00188	CcSEcCtD
Milnacipran—Dermatitis—Bleomycin—lymphatic system cancer	0.00188	0.00188	CcSEcCtD
Milnacipran—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.00187	0.00187	CcSEcCtD
Milnacipran—Asthenia—Carmustine—lymphatic system cancer	0.00187	0.00187	CcSEcCtD
Milnacipran—Hypersensitivity—Vincristine—lymphatic system cancer	0.00183	0.00183	CcSEcCtD
Milnacipran—Haematuria—Methotrexate—lymphatic system cancer	0.0018	0.0018	CcSEcCtD
Milnacipran—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.00179	0.00179	CcSEcCtD
Milnacipran—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00178	0.00178	CcSEcCtD
Milnacipran—Asthenia—Vincristine—lymphatic system cancer	0.00178	0.00178	CcSEcCtD
Milnacipran—Diarrhoea—Carmustine—lymphatic system cancer	0.00178	0.00178	CcSEcCtD
Milnacipran—Nausea—Bleomycin—lymphatic system cancer	0.00177	0.00177	CcSEcCtD
Milnacipran—Asthenia—Mitoxantrone—lymphatic system cancer	0.00174	0.00174	CcSEcCtD
Milnacipran—Dizziness—Carmustine—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Milnacipran—Diarrhoea—Vincristine—lymphatic system cancer	0.0017	0.0017	CcSEcCtD
Milnacipran—Hepatitis—Methotrexate—lymphatic system cancer	0.0017	0.0017	CcSEcCtD
Milnacipran—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.00168	0.00168	CcSEcCtD
Milnacipran—Urethral disorder—Methotrexate—lymphatic system cancer	0.00166	0.00166	CcSEcCtD
Milnacipran—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00166	0.00166	CcSEcCtD
Milnacipran—Vomiting—Carmustine—lymphatic system cancer	0.00166	0.00166	CcSEcCtD
Milnacipran—Dizziness—Vincristine—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Milnacipran—Rash—Carmustine—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Milnacipran—Dermatitis—Carmustine—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Milnacipran—Headache—Carmustine—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Milnacipran—Erythema multiforme—Methotrexate—lymphatic system cancer	0.0016	0.0016	CcSEcCtD
Milnacipran—Eye disorder—Methotrexate—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Milnacipran—Vomiting—Vincristine—lymphatic system cancer	0.00158	0.00158	CcSEcCtD
Milnacipran—Cardiac disorder—Methotrexate—lymphatic system cancer	0.00158	0.00158	CcSEcCtD
Milnacipran—Rash—Vincristine—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Milnacipran—Dermatitis—Vincristine—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Milnacipran—Headache—Vincristine—lymphatic system cancer	0.00156	0.00156	CcSEcCtD
Milnacipran—Nausea—Carmustine—lymphatic system cancer	0.00155	0.00155	CcSEcCtD
Milnacipran—Angiopathy—Methotrexate—lymphatic system cancer	0.00154	0.00154	CcSEcCtD
Milnacipran—Vomiting—Mitoxantrone—lymphatic system cancer	0.00154	0.00154	CcSEcCtD
Milnacipran—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.00153	0.00153	CcSEcCtD
Milnacipran—Rash—Mitoxantrone—lymphatic system cancer	0.00153	0.00153	CcSEcCtD
Milnacipran—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00152	0.00152	CcSEcCtD
Milnacipran—Chills—Methotrexate—lymphatic system cancer	0.00152	0.00152	CcSEcCtD
Milnacipran—Headache—Mitoxantrone—lymphatic system cancer	0.00152	0.00152	CcSEcCtD
Milnacipran—Mental disorder—Methotrexate—lymphatic system cancer	0.00149	0.00149	CcSEcCtD
Milnacipran—Malnutrition—Methotrexate—lymphatic system cancer	0.00148	0.00148	CcSEcCtD
Milnacipran—Nausea—Vincristine—lymphatic system cancer	0.00148	0.00148	CcSEcCtD
Milnacipran—Dysgeusia—Methotrexate—lymphatic system cancer	0.00145	0.00145	CcSEcCtD
Milnacipran—Nausea—Mitoxantrone—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
Milnacipran—Vision blurred—Methotrexate—lymphatic system cancer	0.00139	0.00139	CcSEcCtD
Milnacipran—Leukopenia—Methotrexate—lymphatic system cancer	0.00132	0.00132	CcSEcCtD
Milnacipran—Convulsion—Methotrexate—lymphatic system cancer	0.00128	0.00128	CcSEcCtD
Milnacipran—Chest pain—Methotrexate—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Milnacipran—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Milnacipran—Infection—Methotrexate—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Milnacipran—Nervous system disorder—Methotrexate—lymphatic system cancer	0.00118	0.00118	CcSEcCtD
Milnacipran—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.00118	0.00118	CcSEcCtD
Milnacipran—Skin disorder—Methotrexate—lymphatic system cancer	0.00117	0.00117	CcSEcCtD
Milnacipran—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.00117	0.00117	CcSEcCtD
Milnacipran—Anorexia—Methotrexate—lymphatic system cancer	0.00115	0.00115	CcSEcCtD
Milnacipran—Hypotension—Methotrexate—lymphatic system cancer	0.00113	0.00113	CcSEcCtD
Milnacipran—Insomnia—Methotrexate—lymphatic system cancer	0.00109	0.00109	CcSEcCtD
Milnacipran—Paraesthesia—Methotrexate—lymphatic system cancer	0.00108	0.00108	CcSEcCtD
Milnacipran—Dyspnoea—Methotrexate—lymphatic system cancer	0.00108	0.00108	CcSEcCtD
Milnacipran—Somnolence—Methotrexate—lymphatic system cancer	0.00107	0.00107	CcSEcCtD
Milnacipran—Dyspepsia—Methotrexate—lymphatic system cancer	0.00106	0.00106	CcSEcCtD
Milnacipran—Decreased appetite—Methotrexate—lymphatic system cancer	0.00105	0.00105	CcSEcCtD
Milnacipran—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.00104	0.00104	CcSEcCtD
Milnacipran—Fatigue—Methotrexate—lymphatic system cancer	0.00104	0.00104	CcSEcCtD
Milnacipran—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000986	0.000986	CcSEcCtD
Milnacipran—Urticaria—Methotrexate—lymphatic system cancer	0.000958	0.000958	CcSEcCtD
Milnacipran—Body temperature increased—Methotrexate—lymphatic system cancer	0.000953	0.000953	CcSEcCtD
Milnacipran—Abdominal pain—Methotrexate—lymphatic system cancer	0.000953	0.000953	CcSEcCtD
Milnacipran—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000888	0.000888	CcSEcCtD
Milnacipran—Asthenia—Methotrexate—lymphatic system cancer	0.000865	0.000865	CcSEcCtD
Milnacipran—Pruritus—Methotrexate—lymphatic system cancer	0.000853	0.000853	CcSEcCtD
Milnacipran—Diarrhoea—Methotrexate—lymphatic system cancer	0.000825	0.000825	CcSEcCtD
Milnacipran—Dizziness—Methotrexate—lymphatic system cancer	0.000797	0.000797	CcSEcCtD
Milnacipran—Vomiting—Methotrexate—lymphatic system cancer	0.000767	0.000767	CcSEcCtD
Milnacipran—Rash—Methotrexate—lymphatic system cancer	0.00076	0.00076	CcSEcCtD
Milnacipran—Dermatitis—Methotrexate—lymphatic system cancer	0.00076	0.00076	CcSEcCtD
Milnacipran—Headache—Methotrexate—lymphatic system cancer	0.000755	0.000755	CcSEcCtD
Milnacipran—Nausea—Methotrexate—lymphatic system cancer	0.000716	0.000716	CcSEcCtD
